[go: up one dir, main page]

RS59353B1 - Modulacija aktivnosti komplementa - Google Patents

Modulacija aktivnosti komplementa

Info

Publication number
RS59353B1
RS59353B1 RSP20191263A RS59353B1 RS 59353 B1 RS59353 B1 RS 59353B1 RS P20191263 A RSP20191263 A RS P20191263A RS 59353 B1 RS59353 B1 RS 59353B1
Authority
RS
Serbia
Prior art keywords
modulation
complement activity
complement
activity
Prior art date
Application number
Other languages
English (en)
Inventor
Michelle Denise Hoarty
Ketki Ashok Dhamnaskar
Daniel Elbaum
Kristopher Josephson
Kelley Cronin Larson
Zhong Ma
Nathan Ezekiel Nims
Alonso Ricardo
Kathleen Seyb
Guo-Qing Tang
Douglas A Treco
Zhaolin Wang
Ping Ye
Hong Zheng
Sarah Jacqueline Perlmutter
Robert Paul Hammer
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of RS59353B1 publication Critical patent/RS59353B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RSP20191263 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa RS59353B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
EP15807069.8A EP3154561B1 (en) 2014-06-12 2015-06-12 Modulation of complement activity

Publications (1)

Publication Number Publication Date
RS59353B1 true RS59353B1 (sr) 2019-10-31

Family

ID=54834568

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP20191263 RS59353B1 (sr) 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa
RS20211214A RS62428B1 (sr) 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20211214A RS62428B1 (sr) 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa

Country Status (30)

Country Link
US (7) US10106579B2 (sr)
EP (4) EP3628680B1 (sr)
JP (4) JP6432954B2 (sr)
KR (3) KR102503319B1 (sr)
CN (3) CN111187338B (sr)
AP (1) AP2016009612A0 (sr)
AU (3) AU2015274482B2 (sr)
BR (3) BR112016029076B1 (sr)
CA (3) CA3174909A1 (sr)
CY (3) CY1122227T1 (sr)
DK (2) DK3628680T3 (sr)
ES (2) ES2750556T3 (sr)
FI (1) FIC20240015I1 (sr)
FR (1) FR24C1022I1 (sr)
HR (2) HRP20211561T8 (sr)
HU (3) HUE055931T2 (sr)
IL (3) IL249093B (sr)
LT (2) LT3628680T (sr)
MX (2) MX2016016449A (sr)
NL (1) NL301275I2 (sr)
NZ (1) NZ727420A (sr)
PL (2) PL3628680T3 (sr)
PT (2) PT3628680T (sr)
RS (2) RS59353B1 (sr)
RU (1) RU2670988C2 (sr)
SG (1) SG11201610222UA (sr)
SI (2) SI3628680T1 (sr)
SM (2) SMT202100588T1 (sr)
WO (1) WO2015191951A2 (sr)
ZA (3) ZA201706379B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59353B1 (sr) 2014-06-12 2019-10-31 Ra Pharmaceuticals Inc Modulacija aktivnosti komplementa
HRP20211824T1 (hr) * 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
CN108697759B (zh) 2015-12-16 2022-08-02 Ra制药公司 补体活性的调节剂
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2019246387A1 (en) * 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
CN113226368A (zh) * 2018-10-22 2021-08-06 Ra制药公司 采用齐鲁考普的神经疾病治疗
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3137895A1 (en) * 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
MX2022003013A (es) 2019-09-12 2022-04-07 Ra Pharmaceuticals Inc Tratamiento de enfermedades neurologicas con inhibidores del complemento.
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof
WO2024206786A2 (en) * 2023-03-31 2024-10-03 Flexsys America L.P. Heteroaryl antidegradants

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (sr) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69032483T2 (de) 1989-10-05 1998-11-26 Optein, Inc., Seattle, Wash. Zellfreie synthese und isolierung von genen und polypeptiden
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1994028424A1 (en) 1993-05-28 1994-12-08 Chiron Corporation Method for selection of biologically active peptide sequences
ATE193892T1 (de) 1993-06-29 2000-06-15 Ferring Bv Synthese zyklischer peptide
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1477561B1 (en) 1996-10-17 2008-12-10 Mitsubishi Chemical Corporation Molecule assigning genotype to phenotype and use thereof
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
DE69931930T2 (de) 1998-08-07 2006-10-05 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
AU2003228269A1 (en) * 2002-03-01 2003-09-16 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
NZ568459A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005023866A2 (en) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8652477B2 (en) 2009-10-16 2014-02-18 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
CA2903896A1 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
JP2010505946A (ja) 2006-10-10 2010-02-25 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 神経再生改善のための補体阻害
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
EP2121016A1 (en) * 2007-03-06 2009-11-25 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
JP2010521194A (ja) * 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US20080269318A1 (en) 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
WO2008154251A2 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
CN101854916A (zh) 2007-10-02 2010-10-06 博泰迪亚制药公司 由凝胶持续递送坎普他汀类似物
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
DK2328616T3 (en) * 2008-08-05 2015-07-20 Novartis Ag Compositions and Methods for Antibodies to Complement Protein C5
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102686607B (zh) 2009-12-16 2014-10-29 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2545072B1 (en) 2010-03-12 2017-11-22 The Regents of The University of California Lipid-peptide-polymer conjugates and nanoparticles thereof
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
SG193434A1 (en) * 2011-03-16 2013-10-30 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
NZ617298A (en) 2011-04-08 2015-08-28 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
WO2013052736A2 (en) * 2011-10-06 2013-04-11 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
CA2863862C (en) * 2012-02-20 2021-03-16 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EA201691481A1 (ru) 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
RS59353B1 (sr) * 2014-06-12 2019-10-31 Ra Pharmaceuticals Inc Modulacija aktivnosti komplementa
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3142656B1 (en) 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
CN108697759B (zh) 2015-12-16 2022-08-02 Ra制药公司 补体活性的调节剂
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR ADMINISTERING COMPOUNDS
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3137895A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
US11014965B2 (en) 2021-05-25
KR20190057420A (ko) 2019-05-28
BR122021025449B1 (pt) 2024-02-15
KR20170003993A (ko) 2017-01-10
KR102346228B1 (ko) 2022-01-04
US20190119328A1 (en) 2019-04-25
PT3154561T (pt) 2019-10-25
US10562934B2 (en) 2020-02-18
SMT202100588T1 (it) 2021-11-12
US11965040B2 (en) 2024-04-23
LT3628680T (lt) 2021-11-25
BR122023024819A2 (pt) 2023-12-26
EP3628680B1 (en) 2021-09-08
AU2019200828A1 (en) 2019-02-28
CY2024015I1 (el) 2024-12-13
KR20220002727A (ko) 2022-01-06
BR112016029076A8 (pt) 2022-02-08
EP4223317A2 (en) 2023-08-09
US20200123202A1 (en) 2020-04-23
PT3628680T (pt) 2021-10-07
LT3154561T (lt) 2019-11-25
AU2015274482A1 (en) 2017-01-12
IL273746A (en) 2020-05-31
RU2670988C2 (ru) 2018-10-29
AU2019200828B2 (en) 2021-04-08
RS62428B1 (sr) 2021-11-30
US10435438B2 (en) 2019-10-08
NZ736573A (en) 2024-03-22
CY1122227T1 (el) 2020-11-25
RU2016147080A3 (sr) 2018-06-01
FIC20240015I1 (fi) 2024-05-28
CA3174909A1 (en) 2015-12-17
RU2018136750A3 (sr) 2021-10-19
EP3628680A1 (en) 2020-04-01
KR102503319B1 (ko) 2023-02-28
RU2016147080A (ru) 2018-06-01
US11535650B1 (en) 2022-12-27
JP7002597B2 (ja) 2022-02-04
EP3154561A4 (en) 2018-04-18
US20200002380A1 (en) 2020-01-02
ZA201706379B (en) 2018-12-19
CN111187338A (zh) 2020-05-22
MX2021009309A (es) 2021-10-26
HUS2400015I1 (hu) 2024-06-28
ZA202001859B (en) 2021-04-28
CN106456701A (zh) 2017-02-22
EP4223317A3 (en) 2023-09-27
BR112016029076B1 (pt) 2024-02-15
US20180371019A1 (en) 2018-12-27
CN106456701B (zh) 2020-01-07
DK3154561T3 (da) 2019-10-07
DK3628680T3 (da) 2021-10-11
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
SMT201900568T1 (it) 2019-11-13
NZ727420A (en) 2018-06-29
JP7454545B2 (ja) 2024-03-22
HRP20191763T1 (hr) 2019-12-27
CA3241273A1 (en) 2015-12-17
JP2020128417A (ja) 2020-08-27
IL249093A0 (en) 2017-01-31
SI3154561T1 (sl) 2019-11-29
HRP20211561T1 (hr) 2021-12-24
CA2949985C (en) 2023-10-17
CN111187338B (zh) 2024-08-02
HUE055931T2 (hu) 2022-01-28
AU2015274482B2 (en) 2018-11-08
CY2024015I2 (el) 2024-12-13
SI3628680T1 (sl) 2021-12-31
US20170137468A1 (en) 2017-05-18
EP3973994A1 (en) 2022-03-30
EP3154561B1 (en) 2019-09-04
SG11201610222UA (en) 2017-01-27
AP2016009612A0 (en) 2016-12-31
ES2895029T3 (es) 2022-02-17
JP2017523232A (ja) 2017-08-17
AU2021204313A1 (en) 2021-07-22
IL281264B (en) 2022-05-01
JP6770043B2 (ja) 2020-10-14
CA2949985A1 (en) 2015-12-17
JP6432954B2 (ja) 2018-12-05
WO2015191951A3 (en) 2016-03-03
PL3154561T3 (pl) 2019-12-31
FR24C1022I1 (fr) 2024-07-19
US10106579B2 (en) 2018-10-23
HRP20211561T8 (hr) 2022-03-04
ZA201900497B (en) 2019-10-30
US20210246167A1 (en) 2021-08-12
WO2015191951A2 (en) 2015-12-17
EP3154561A2 (en) 2017-04-19
ES2750556T3 (es) 2020-03-26
IL249093B (en) 2020-05-31
NL301275I2 (nl) 2024-06-20
US10208089B2 (en) 2019-02-19
IL281264A (en) 2021-04-29
HUE045646T2 (hu) 2020-01-28
KR101981532B1 (ko) 2019-09-02
MX2016016449A (es) 2017-08-24
NZ761610A (en) 2024-03-22
AU2021204313B2 (en) 2024-01-04
RU2018136750A (ru) 2018-11-06
PL3628680T3 (pl) 2022-01-10
JP2022034057A (ja) 2022-03-02
CN119236050A (zh) 2025-01-03
BR112016029076A2 (pt) 2018-06-05
JP2019048834A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
HUS2400015I1 (hu) Komplement aktivitás modulálása
IL259762B (en) Complement activity modulators
HK1246672A1 (zh) 補體活性的調節劑
PL3359556T3 (pl) Modulowanie aktywności gamma-c-cytokin
SG11201607445QA (en) Methods of modulating wars2
PT3377106T (pt) Modulação da ciliogénese